Navigation Links
Strategic Diagnostics Updates Roth Conference Presentation Time

Scheduled to present at 3 p.m. based on updated agenda

NEWARK, Del., Aug. 22 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) -- a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, environmental and life science applications, announced today that due to a change in the conference agenda, SDI's presentation at the Roth Capital Partner's Roth 2007 New York Conference at the Westin Hotel in Manhattan is now scheduled for 3 p.m. on Sept 5, 2007 in the Majestic II (Track 1) room.

The presentation will be webcast at for approximately 30 days following the conclusion of the presentation. Following the presentation, Mr. Knight will attend a breakout session. One-on-one meetings may be scheduled through Roth Capital Partners by calling (949) 720-5700.

Each presentation is designed to provide analysts, institutional brokers and portfolio managers with an overview of the Company's expertise in the production of antibodies, used both in diagnostic tests and provided to the proteomics, pharmaceutical, diagnostics and biomedical research industries to enable rapid discovery and commercialization of products. Strategic Diagnostics is a leader in the food pathogen industry, providing comprehensive, accurate, and easy-to-use tests including the recently introduced RapidChek(R) SELECT(TM) Salmonella product. The Company is also an emerging leader in producing monoclonal and polyclonal antibodies for the pharmaceutical and research industries. The Company's patent-pending technology also addresses renewable energy opportunities and can be used to increase efficiency in the production of ethanol. Management will discuss the recurring revenue component of the Company's business model, revenue potential from new product and services, and the Company's strategy for sustainable growth.

About the Roth Capital Partners and the 2007 New York Conference

Roth is one of the last remaining independent full-service investment banks dedicated to the small and micro-cap market. The firm is privately owned with current principals being majority owners. The core management team has been consistent for many years. Since the inception of the firm in 1984, Roth has been a leader and innovator in the small and micro cap markets. Roth's exclusive focus has been, is, and will continue to offer a full spectrum of investment banking services, including raising capital, research coverage, trading and market making, merger and acquisition advisory services, and investor conferences. Roth's award-winning research is the foundation of its firm and key to its understanding of the micro-and small- cap sector. This research, when combined with a seasoned institutional sales team and its highly visible investor conferences, creates an unparalleled institutional sponsorship platform for growth companies. Roth has raised more than $10 billion for small and micro cap public companies and completed over 135 merger, acquisition and advisory assignments. Since year 2000, Roth has been a leading placement agent for the number of PIPE transactions, raising over $2 billion for its clients. Roth received top 20 IPO aftermarket performance rankings for six consecutive years from 1994 to 1999. The 5th Annual New York Conference is a two-day event with more than 230 presenting companies and is attended by over 1,200 buy side investors. The 2006 conference had more than 2,000 one-on-one meetings.

About Strategic Diagnostics Inc.

Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in proteomics research and discovery.

This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project", "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.

Company Contact: Investor Contact:

Stan Fronczskowski Hayden Communications

Chief Financial Officer Brett Maas (

(302) 456-6789 (646) 536-7331

SOURCE Strategic Diagnostics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Technology and mergers: Getting the strategic applications
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. A prognosis for GE and Abbott Diagnostics
5. The world of in-vitro diagnostics is another Midwest success story
6. The world of in vitro diagnostics is another Midwest success story
7. Midwest holds strong position in worldwide diagnostics business
8. BioDiagnostics is first seed-testing lab to gain new accreditation
9. Merge announces sofware updates, upcoming acquisition
10. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
11. Solinus updates MailFoundry anti-spam hardware, switching to Linux
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):